INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 160 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $651 | -58.3% | 35,087 | -75.2% | 0.01% | -53.8% |
| Q2 2023 | $1,562 | +49.9% | 141,219 | +82.1% | 0.01% | +44.4% |
| Q1 2023 | $1,042 | -84.1% | 77,558 | -85.4% | 0.01% | -90.5% |
| Q4 2022 | $6,563 | -99.4% | 530,567 | +532.1% | 0.10% | +533.3% |
| Q3 2022 | $1,171,000 | +107.3% | 83,939 | +141.6% | 0.02% | +114.3% |
| Q1 2022 | $565,000 | -78.0% | 34,745 | -78.0% | 0.01% | -74.1% |
| Q4 2021 | $2,568,000 | +504.2% | 157,663 | +450.6% | 0.03% | +350.0% |
| Q3 2021 | $425,000 | +100.5% | 28,633 | +169.2% | 0.01% | +200.0% |
| Q2 2021 | $212,000 | -49.2% | 10,635 | -41.1% | 0.00% | -66.7% |
| Q1 2021 | $417,000 | -10.9% | 18,055 | -4.6% | 0.01% | +20.0% |
| Q4 2020 | $468,000 | -76.1% | 18,929 | -53.8% | 0.01% | -90.2% |
| Q2 2020 | $1,961,000 | +623.6% | 40,941 | +1104.1% | 0.05% | +363.6% |
| Q2 2019 | $271,000 | +34.8% | 3,400 | +89.3% | 0.01% | -26.7% |
| Q1 2019 | $201,000 | – | 1,796 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |